Diabetes drugs for nonalcoholic fatty liver disease: a systematic review

BACKGROUND: Fatty liver is associated with obesity, type 2 diabetes, hyperlipidemia, hypertension, and metabolic syndrome. While there are no approved drugs for the treatment of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis, strategies to ameliorate fatty liver often targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Blazina, Ian, Selph, Shelley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884753/
https://www.ncbi.nlm.nih.gov/pubmed/31783920
http://dx.doi.org/10.1186/s13643-019-1200-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884753/
https://www.ncbi.nlm.nih.gov/pubmed/31783920
http://dx.doi.org/10.1186/s13643-019-1200-8

Ejemplares similares